Has Susan Bostick, MD received payments from drug or device companies?

Yes. Drug and device makers reported $17,443 in general payments to Susan Bostick, MD across 1,018 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Susan Bostick, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Susan Bostick, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Susan Bostick, MD

Medical Oncology · Tuscaloosa, ALNPI 1659582369

Payments from drug & device makers

$17,443in general payments, 2019–2025

Across 1,018 payments — averaging $17.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Novartis$2K
E.r. Squibb & Sons, L.L.C.$1K
AstraZeneca$1K
Pfizer$1K
Merck$941
Incyte Corporation$641
plus $10K from 54 others

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Novartis	112	$1,835
E.r. Squibb & Sons, L.L.C.	97	$1,382
AstraZeneca(2 entities)	65	$1,197
Pfizer	76	$1,041
Merck	59	$941
Incyte Corporation	30	$641
Daiichi Sankyo Inc.	40	$633
GSK	34	$595
Johnson & Johnson(2 entities)	30	$534
Seagen Inc.	32	$532
AbbVie	21	$516
Amgen	30	$488
Bristol Myers Squibb	24	$428
Sanofi	22	$418
Genentech USA, Inc.	22	$414
Pharmacyclics LLC, An Abbvie Company	23	$351
Gilead(2 entities)	20	$327
Eisai Inc.	20	$326
Lilly USA, LLC	19	$316
Regeneron Healthcare Solutions, Inc.	17	$303
Bayer	17	$295
Exelixis Inc.	15	$282
Blueprint Medicines Corporation	11	$257
Takeda Pharmaceuticals U.S.A., Inc.	8	$191
Stemline Therapeutics Inc.	7	$161
Pharmaessentia USA Corporation	6	$148
Boehringer Ingelheim	6	$144
Deciphera Pharmaceuticals Inc.	7	$141
Array Biopharma Inc	9	$137
Beigene USA, Inc.	8	$131
Karyopharm Therapeutics Inc.	7	$129
Myriad Genetic Laboratories, Inc.	6	$121
Astellas Pharma US Inc	6	$119
Beone Medicines USA, Inc.	6	$103
Progenics Pharmaceuticals, Inc.	6	$102
Jazz Pharmaceuticals Inc.	4	$102
EMD Serono, Inc.	6	$88
Acrotech Biopharma Inc.	5	$79
Tersera Therapeutics LLC	4	$77
Ipsen Biopharmaceuticals, Inc	4	$70
ADC Therapeutics America, Inc.	4	$68
Sobi, Inc	3	$66
Puma Biotechnology, Inc.	4	$64
Rigel Pharmaceuticals, Inc.	3	$64
Servier Pharmaceuticals LLC	4	$63
Dova Pharmaceuticals	3	$58
Coherus Oncology, Inc.	3	$56
AVEO Pharmaceuticals, Inc.	3	$49
Agios Pharmaceuticals, Inc.	3	$49
Sun Pharmaceutical Industries Inc.	2	$47
Genmab U.S., Inc.	3	$47
Myovant Sciences Inc.	3	$46
Taiho Oncology, Inc.	3	$44
Pharmacosmos Therapeutics Inc.	2	$43
Shield Therapeutics Inc	2	$37
Tolmar Pharmaceuticals, Inc.	2	$37
Mirati Therapeutics, Inc.	2	$36
Adaptive Biotechnologies Corporation	2	$35
Spectrum Pharmaceuticals Inc.	2	$30
Immunocore Limited	1	$30

How this compares

$17,443 in reported general payments places this provider in the 55th percentile of 30 medical oncology providers in Alabama.

See all medical oncology providers in Alabama →

Medicare billing

Part B allowed, 2024

$86,352

Medicare patients

459

Services billed

986

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other medical oncology in Tuscaloosa

John DubayTuscaloosa$756K
David HintonTuscaloosa$16K
Ariel AnguianoTuscaloosa$8K
Edgar PrasthoferTuscaloosa$834
Ajay TadepalliTuscaloosa$177
Syed Abbas AliJasper$3M
Joelle HamiltonHomewood$2.2M
Sachin PaiMobile$2.1M
Marshall SchreederHuntsville$1.1M
Pranitha ProdduturvarMobile$910K

See the full list for Alabama →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →